0

Back to BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use
BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use

BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use

Intended audience: clinical laboratory scientists, pathologists
  • List Price: $20.00
  • Member Price: $15.00
 
Want to save more?
Log into see if you qualify for a lower rate.
Members save $5.00 or more Join
Item Details:

Educational objectives:

  • Recognize B-lymphoblastic leukemia/lymphoma, BCR-ABL1¬-like (Ph-like ALL), a provisional entity in the 2016 revision to the World Health Organization (WHO) Classification of Tumours of Haematopoietic and Lymphoid Tissues.
  • Define methodologies useful in the identification of...
Back to BCR-ABL1-like B-Lymphoblastic Leukemia/Lymphoma with FOXP1-ABL1 Rearrangement: Comprehensive Laboratory Identification Allowing Tyrosine Kinase Inhibitor Use
View More View Less

Bought This Bought That ...